AIDS Therapies

Three Drugs Better, and More Expensive, Than Two in Fighting HIV

Published in AIDS Weekly, September 22nd, 1997

Two studies show conclusively that a triple drug treatment can reduce the amount of AIDS causing virus in the blood dramatically and lower the risk of death for at least a year.

What the studies in the September 4, 1997, issue of the New England Journal of Medicine did not address was how most of the millions of people around the world infected with HIV could afford the estimated $10,000 to $12,000 annual treatment.

The three drugs involved in the cocktail are: indinavir, sold under the brand name Crixivan by Merck & Co. Inc.; lamivudine, sold as Epivir or 3TC by Glaxo-Wellcome Plc, and another Glaxo product, AZT, known as zidovudine or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-09-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry